Clene Inc Ordinary Shares CLNN
News
Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS
Clene to Present at Upcoming Investor Conferences
Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
Clene Announces $4 Million Registered Direct Offering
Clene to Present at Upcoming September Investor Conferences
Clene to Present at the Emerging Growth Conference
Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval
